Success Metrics

Clinical Success Rate
81.8%

Based on 9 completed trials

Completion Rate
82%(9/11)
Active Trials
3(14%)
Results Posted
44%(4 trials)
Terminated
2(10%)

Phase Distribution

Ph early_phase_1
2
10%
Ph phase_1
2
10%
Ph phase_2
6
29%
Ph phase_3
5
24%
Ph not_applicable
4
19%
Ph phase_4
2
10%

Phase Distribution

4

Early Stage

6

Mid Stage

7

Late Stage

Phase Distribution21 total trials
Early Phase 1First-in-human
2(9.5%)
Phase 1Safety & dosage
2(9.5%)
Phase 2Efficacy & side effects
6(28.6%)
Phase 3Large-scale testing
5(23.8%)
Phase 4Post-market surveillance
2(9.5%)
N/ANon-phased studies
4(19.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

9 of 12 finished

Non-Completion Rate

25.0%

3 ended early

Currently Active

3

trials recruiting

Total Trials

21

all time

Status Distribution
Active(4)
Completed(9)
Terminated(3)
Other(5)

Detailed Status

Completed9
unknown5
Recruiting2
Terminated2
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
3
Success Rate
81.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (9.5%)
Phase 12 (9.5%)
Phase 26 (28.6%)
Phase 35 (23.8%)
Phase 42 (9.5%)
N/A4 (19.0%)

Trials by Status

withdrawn15%
recruiting210%
active_not_recruiting15%
completed943%
terminated210%
not_yet_recruiting15%
unknown524%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT04804644Phase 3

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

Recruiting
NCT04966546Early Phase 1

Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD)

Withdrawn
NCT03553875Phase 3

Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions

Terminated
NCT07351773Not Applicable

Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease

Completed
NCT04939597Phase 3

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

Active Not Recruiting
NCT07164794Phase 2

Memantine Hydrochloride in Prostate Cancer Patients

Not Yet Recruiting
NCT06789757Phase 2

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

Recruiting
NCT01430351Phase 1

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

Terminated
NCT04217694Early Phase 1

Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

Completed
NCT06337994Phase 3

Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury

Completed
NCT05531383Not Applicable

Effect of Early Memantine Administration on Outcome of Patients With Moderate to Severe Traumatic Brain Injury

Unknown
NCT01535040Phase 2

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

Completed
NCT04801342Phase 2

Neurocognitive Outcome of Bilateral or Unilateral Hippocampal Avoidance WBRT With Memantine for Brain Metastases

Unknown
NCT04417543Phase 1

Effect of Memantine on Cognitive Impairment in Patients With Epilepsy

Completed
NCT03247218Phase 2

A Phase - IIa - IIb, Trial to Study the Safety, Tolerability and Efficacy of Memantine as a Long-term Treatment of SCD

Unknown
NCT03168997Phase 4

Memantine Treatment in Alzheimer's Disease Patients

Unknown
NCT01533493Not Applicable

Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study

Completed
NCT00585169Phase 2

Memantine Treatment Study of Pathological Gambling

Completed
NCT00586573Phase 4

Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS

Completed
NCT00594737Phase 3

Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia

Completed

Drug Details

Intervention Type
DRUG
Total Trials
21